KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Benzer Materyaller

• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  Yazar:: Pao, William, ve diğerleri
  Baskı/Yayın Bilgisi: (2005)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  Yazar:: Zakowski, Maureen F., ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Yazar:: Pao, William, ve diğerleri
  Baskı/Yayın Bilgisi: (2004)
• Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
  Yazar:: Janjigian, Yelena Y., ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Association of KRAS and EGFR Mutations with Survival in Patients with Advanced Lung Adenocarcinomas
  Yazar:: Johnson, Melissa L., ve diğerleri
  Baskı/Yayın Bilgisi: (2012)